Virometix AG
8952 Schlieren, Wagistrasse 14
+41 (0)43 433 86 60
info@virometix.com
Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.
Virometix AG
Wagistrasse 14
8952 Schlieren
10 Ergebnisse für "immunotherapeutic" unter Virometix AG
Microsoft Word - Virometix_Press Release-V-306 Phase I Trial-1st Co...
... biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and ... company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and ... biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and ... company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and ...
Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
24 Ergebnisse für "immunotherapeutic" unter Somagenetix
UZH - CRPP ImmunoCure - Miachael Weller
... immunotherapeutic agents in brain tumors. Furthermore, novel treatment strategies are assessed in patients with ... newly diagnosed and recurrent glioblastoma. Overcoming resistance of gliomas to immunotherapeutic ... chemo- and immunotherapeutic agents in brain tumors. Furthermore, novel treatment strategies are ... immunotherapeutic strategies Development of novel drugs in early clinical trials Design and conductance of late ...
UZH - CRPP ImmunoCure - Patrick Roth
... : University Hospital Zurich Department of Neurology Frauenklinikstrasse 26 CH-8091 Zurich Immunotherapeutic ... the immune system with a particular focus on novel immunotherapeutic strategies. The following ... Department of Neurology Frauenklinikstrasse 26 CH-8091 Zurich patrick.roth@usz.ch Immunotherapeutic ... the immune system with a particular focus on novel immunotherapeutic strategies. The following ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
16 Ergebnisse für "immunotherapeutic" unter University of Zurich
UZH - CRPP ImmunoCure
... immunotherapeutic strategies for various types of cancer including brain tumors and hematological malignancies. A ... groups aiming at the development of novel immunotherapeutic strategies for various types of cancer ... CAR T cells and other antibody-based immunotherapeutic strategies in appropriate preclinical models ...
Frequent PD-L1 expression in testicular germ cell tumors - Zurich O...
... immunotherapeutic strategies. METHODS Immunohistochemistry was performed in 479 formalin-fixed paraffin-embedded ... immunotherapeutic strategies using anti-PD1 and anti-PDL1 antibodies. Abstract BACKGROUND Many testicular germ cell ... immunotherapeutic strategies. METHODS Immunohistochemistry was performed in 479 formalin-fixed paraffin-embedded ... immunotherapeutic strategies using anti-PD1 and anti-PDL1 antibodies. Abstract BACKGROUND Many testicular germ cell ...
University Hospital Zurich, Research and Education Office
https://www.usz.ch/forschung/Seiten/default.aspx
8091 Zürich, Rämistrasse 100
The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.
University Hospital Zurich, Research and Education Office
Rämistrasse 100
8091 Zürich
19 Ergebnisse für "immunotherapeutic" unter University Hospital Zurich, Research and Education Office
5th Zurich Immuno-Oncology Symposium – Universitätsspital Zürich
... development of new immunotherapeutic agents requires a multidisciplinary approach. Standort 16.30-18:30 Uhr ... development of new immunotherapeutic agents requires a multidisciplinary approach. Standort Virtual Live ...
New Portfolio Start-Up: Stromal Therapeutics – USZ
... stroma. Stromal Therapeutics is developing novel Immunotherapeutic medicines to treat chronic ... developing novel Immunotherapeutic medicines to treat chronic inflammatory diseases. With their unique domain ...
ETH Zürich - Feasibility Lab
Technoparkstrasse 1
8005 Zürich
9 Ergebnisse für "immunotherapeutic" unter ETH Zürich - Feasibility Lab
Infozentrum: Katalog
... Seiten 351 ISBN Medium Paperback Standort Food Allergy Medium Glioma : Immunotherapeutic Approaches ... Glioma : Immunotherapeutic Approaches Verlag Medium Annals of the New York Academy of Sciences ... Experimental Medicine and Biology Glioma : Immunotherapeutic Approaches 2012 e-Book Yamanaka Ryuya Advances in ... Experimental Medicine and Biology Glioma : Immunotherapeutic Approaches Klassifikation Biowissenschaften ...
Infozentrum: Katalog
... Verlag Springer-Verlag Jahr 2013 Seiten 183 ISBN Medium Resistance to Immunotherapeutic Antibodies in ... Cancer : Strategies to Overcome Resistance Resistance to Immunotherapeutic Antibodies in Cancer ... Targeted Anti-Cancer Therapeutics Resistance to Immunotherapeutic Antibodies in Cancer : Strategies to ... Resistance to Immunotherapeutic Antibodies in Cancer : Strategies to Overcome Resistance Klassifikation ...
ImmunOs Therapeutics AG
http://immunostherapeutics.com/
8952 Schlieren, Wagistrasse 14
ImmunOs Therapeutics AG is a clinical-stage biotechnology company developing the next generation of novel immunotherapies that enhance the efficacy of market leading checkpoint inhibitors and costimulatory agonists for cancer therapy. The company is actively discussing and exploring new strategic collaborations with leading global pharmaceutical companies.
ImmunOs Therapeutics AG
Wagistrasse 14
8952 Schlieren
3 Ergebnisse für "immunotherapeutic" unter ImmunOs Therapeutics AG
Company
... mission is to convert first-in-class immunotherapeutic targets into exploitable drug candidates. Our team ... . ImmunOs Therapeutics AG mission is to convert first-in-class immunotherapeutic targets into exploitable ...
Scientific Advisory Board - Immunostherapy
... immunotherapeutic antibodies based on novel targets and preclinical reagents originating at MD Anderson. He also has ... , which coordinates development and production of clinical immunotherapeutic antibodies based on novel ...
InSphero AG
8952 Schlieren, Wagistrasse 27
+41 44 515049-0
info@insphero.com
InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company currently counts all of the top ten global pharmaceutical and cosmetics companies as customers and is helping them to implement its patented microtissue technology in their development work-flow.
InSphero AG
Wagistrasse 27
8952 Schlieren
Roche Glycart AG
https://www.roche.ch/en/sites/schlieren
8952 Schlieren, Wagistrasse 10
+41 43 215 10 00
The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.
Roche Glycart AG
Wagistrasse 10
8952 Schlieren
2 Ergebnisse für "immunotherapeutic" unter Roche Glycart AG
VENTANA MMR RxDx Panel (CE IVD)
... immunotherapeutic option for patients.8 Multiple studies have demonstrated that MMR deficiency correlate with higher ... deficiency serves as a predictive biomarker for a new immunotherapeutic option for patients. 8 Multiple ...
VENTANA MMR RxDx Panel (US FDA Approved)
... eLabDoc. MMR deficiency serves as a predictive biomarker for a new immunotherapeutic option for patients.1 ... eLabDoc . Visit eLabDoc MMR deficiency serves as a predictive biomarker for a new immunotherapeutic option ...
NEXUS Personalized Health Technologies
8952 Schlieren, Wagistrasse 18
+41 44 632 21 61
stekhoven@nexus.ethz.ch
NEXUS Personalized Health Technologies is an ETH Technology Platform created to enable and accelerate the execution of translational research projects by providing key technological resources, tools and collaboration opportunities for the personalized health research community. NEXUS is built around two interdisciplinary technology units that are staffed with professional scientists: Theragnostics Discovery and Clinical Bioinformatics.
NEXUS Personalized Health Technologies
Wagistrasse 18
8952 Schlieren
1 Ergebnisse für "immunotherapeutic" unter NEXUS Personalized Health Technologies
NEXUS User Seminar – NEXUS Personalized Health Technologies | ETH Zurich
... alternative splicing in generating tumor markers that are targetable with immunotherapeutic approaches. After ... immunotherapeutic approaches. After translating all RNA-sequences generated by novel introns into protein space, we ...
ETH Zürich - Numerische Materialmodellierung
8005 Zürich, Technoparkstrasse 1 / Einstein PFA G 11 (2. OG)
ETH Zürich - Numerische Materialmodellierung
Technoparkstrasse 1
8005 Zürich